AI Native Biopharma Advancing Global and Misutilized AssetsAI NativeBiopharmaAdvancing GlobalandMisutilized Assets
A Quantitative AI Engine that Systematizes the Search, Evaluation, and Development of Pharma assets.
We work where biology
is hardest, and bring back
candidates that translate.
Approach
A self-optimizing research initiative in the optimization of pharma supply, distribution, and value creation. From ecology, to marine biology, to in-silico testing and policy and economic changes, an AI agent pharma ontology built for seeing opportunities throughout the noise.
Ten thousand diseases. A few hundred answers.
The disease landscape is vast.
Researchers have documented on the order of ten thousand distinct human diseases. They span every organ system, every population, and every level of prevalence, from conditions affecting hundreds of millions of people to those described in only a handful of families.
The universe of approved drugs is small.
Only a few hundred of those diseases have even one approved therapy. For the overwhelming majority, standard of care means managing symptoms, using something off-label, or nothing at all. Measured against the landscape, the treated portion is a rounding error.
And the gap is not being filled.
New approvals concentrate in a narrow band of well-understood, well-funded indications. Meanwhile, assets with real data sit idle because the economics, the geography, or the timing never lined up. The science to close part of this gap already exists. It is the matching that is missing.
What we bring.
Your asset gets a company of its own, run by operators whose only mandate is advancing it.
Proximity to the FDA and access to the deepest life-sciences capital markets in the world.
You hold equity and milestone participation, so we succeed only when the program does.
Become a partner.
We partner with pharma, foundation, and venture-backed programs on co-developed discovery and translational work. New engagements typically begin with a two-week feasibility sprint.